Air Purifier for Cancer Patients — H13 HEPA, Aspergillus Risk, and Immunocompromised Home Air Quality

Neutropenia From Chemotherapy Creates Severe Susceptibility to Airborne Aspergillus Fumigatus Conidia

Cancer patients undergoing chemotherapy or bone marrow transplantation often develop neutropenia — a condition in which the ANC falls below 500 cells per µL. Neutrophils are the primary immune defense against fungal infections; when their count collapses, the body loses the ability to contain inhaled fungal spores before they germinate and invade tissue. This is a fundamentally different clinical scenario from the obstructive lung disease seen in COPD patients, where the primary pathophysiology is airflow limitation, not immunosuppression. For neutropenic cancer patients, the threat is infectious invasion — not obstruction.

Aspergillus fumigatus is a ubiquitous environmental mold whose conidia (spores) measure 2–3.5 µm in diameter — well within the inhalable range for deep lung penetration. In a healthy individual, inhaled conidia are cleared within hours by alveolar macrophages and neutrophil activity. In a neutropenic patient with ANC below 100 cells per µL — the threshold for profound neutropenia — this clearance mechanism is absent. The conidia germinate, form hyphae, invade blood vessel walls, and can cause disseminated IPA. Reported mortality rates for untreated IPA in immunocompromised patients range from 30% to 90% depending on the depth of immunosuppression and speed of antifungal intervention (Patterson et al., 2016).

This page focuses specifically on the air quality dimension of home management for immunocompromised cancer patients. It is not medical advice. All infection control decisions should be made with the patient oncologist and, where applicable, the transplant team infection control nurse.

Airborne Pathogen Size Versus HEPA Filter Grade — Capture Efficiency for Immunocompromised-Relevant Particles

The key insight from the table: Aspergillus fumigatus conidia at 2–3.5 µm are well above the HEPA MPPS challenge point of 0.3 µm. True H13 HEPA captures them at ≥99.95%. The question for immunocompromised patients is not whether HEPA captures Aspergillus — it does — but whether the filter grade provides sufficient margin given that a single viable conidium reaching an alveolus in a profoundly neutropenic patient may initiate IPA. This is the argument for H14 or HyperHEPA in the most vulnerable patients.

For a complete explanation of HEPA grade designations, capture efficiencies, and the distinction between H13, H14, and HyperHEPA, see HEPA filter grades — H13 vs H14 vs HyperHEPA and what each grade captures.

HEPA Filter Grade Selection for Immunocompromised Patients — H13 Is the Minimum, H14 Provides Additional Margin

HEPA is not a single standard. The EN 1822 classification system (adopted as the reference standard internationally for high-efficiency particulate air filtration) defines filter grades by minimum capture efficiency at the MPPS — the particle size that is hardest to capture, typically 0.1–0.3 µm depending on filter design. For immunocompromised patients, the choice of grade is a clinical safety question, not a consumer preference question.

HEPA Grade Comparison — Capture Efficiency, Home Availability, and Immunocompromised Suitability

The distinction between H13 and H14 matters most at the MPPS of approximately 0.1–0.3 µm — the range where virus-sized particles and the smallest bacterial fragments exist. Aspergillus fumigatus conidia at 2–3.5 µm are captured at very high efficiency by both H13 and H14. The marginal benefit of H14 for fungal spore capture is therefore more about system integrity (filter media consistency, bypass leakage prevention) than raw particle capture rate at that size. For influenza and other respiratory viruses that co-threaten immunocompromised patients, the H14 margin at sub-micron sizes is more meaningful.

Terms such as HEPA-type, HEPA-like, 99% HEPA, or medical-grade HEPA without a specific EN 1822 grade designation should be treated as marketing language. Verify the actual filter grade specification before purchasing for an immunocompromised patient.

See hospital-grade air purifier — HEPA standards used in medical settings for the complete comparison between residential HEPA standards and clinical-grade filtration specifications.

Hospital Oncology Units Use 12 ACH or Greater — Home Purifiers Cannot Match Clinical Standards but 4 to 8 ACH in the Bedroom Is Achievable

The ventilation standard for healthcare facilities in the United States is ASHRAE 170-2021, which specifies minimum ACH requirements by room type. Oncology patient rooms require a minimum of 12 ACH. Bone marrow transplant units require ≥15 ACH with positive pressure and 100% outdoor air (no recirculation). These rooms also filter all supply air through HEPA. The home environment cannot replicate this standard — it is a statement of fact, not a failure of home air purifiers. The home goal is reducing Aspergillus conidia concentration in the immediate sleeping environment, not replicating hospital isolation.

ACH Comparison — Hospital Standard vs Home Achievable Rates

To calculate the CADR needed to achieve a target ACH in a specific room: multiply the room volume (length × width × ceiling height in cubic feet) by the target ACH, then divide by 60 to get required CADR in CFM. A 150 sq ft bedroom with 8 ft ceilings has a volume of 1,200 cubic feet. To achieve 4 ACH: 1,200 × 4 / 60 = 80 CFM CADR minimum. To achieve 8 ACH: 160 CFM minimum. Most mid-to-large residential air purifiers with CADR smoke ratings of 150–300 CFM can achieve 4–8 ACH in a standard bedroom.

The bedroom where the patient sleeps is the highest priority room. The patient spends the greatest number of hours there, the immune system is most active during sleep, and it is the space that can be most practically controlled for air quality. Additional purifiers in the living area or common spaces provide incremental benefit.

For context on what medical organizations advise regarding home air quality interventions, see air purifier doctor recommendations — what medical organizations advise about indoor air quality.

Ionizers and Ozone-Generating Devices Are Contraindicated for Cancer Patients With Respiratory Compromise

Chemotherapy and radiation therapy compromise the respiratory system through multiple mechanisms. Chemotherapy-induced mucositis affects the mucosal lining of the respiratory tract. Certain chemotherapy agents (bleomycin, busulfan, carmustine) are directly pulmonary toxic. Radiation to the chest can cause radiation pneumonitis. The result is a patient population whose lung tissue is already under oxidative and inflammatory stress — exactly the population for whom ozone exposure is most dangerous.

Ozone (O₃) is a reactive oxidant gas. The CARB standard for air cleaners limits ozone output to 0.050 ppm. Even at concentrations below this limit, ozone causes airway inflammation, reduces lung function, and exacerbates respiratory conditions. For a cancer patient with already-compromised lung tissue and mucositis, any ozone exposure adds oxidative burden to a system with reduced repair capacity. Ozone-generating devices have no role in the home of an immunocompromised cancer patient.

Air Purifier Technology Safety for Immunocompromised Cancer Patients

When purchasing a unit for a cancer patient, review the specification sheet for ionizer function. Many HEPA units include an optional ionizer that may be enabled by default. Disable this function permanently. If the ionizer cannot be disabled, the unit is not suitable for this use case. For a comprehensive list of zero-ozone certified units, see ozone free air purifier — why ozone-generating devices are contraindicated for respiratory-compromised individuals.

HEPA Filter Maintenance for Immunocompromised Patients Requires Strict Replacement Intervals and Glove Use

For immunocompromised cancer patients, HEPA filter maintenance is not a matter of air quality optimization — it is an infection control procedure. A saturated HEPA filter that has accumulated biological material over months of operation can become a reservoir. If the filter is damaged (torn, incorrectly seated, or improperly changed), trapped pathogens including Aspergillus spores can be re-aerosolized and released back into the room. This is the opposite of the intended effect.

Filter Change Protocol for Immunocompromised Households

• Follow the manufacturer-specified replacement interval strictly — do not extend filter life beyond the recommended period even if the filter appears clean visually. HEPA efficiency decreases when the filter media is saturated, and the filter cannot be evaluated by visual inspection.
• If the patient is severely neutropenic (ANC below 100 cells per µL), consider reducing the filter change interval by 25–50% from the standard recommendation to ensure a consistent high-capture margin is maintained.
• Wear disposable gloves when handling a used HEPA filter. The exterior of a used HEPA filter contains concentrated particulate material including biological matter accumulated over its operational life.
• The patient should not be present in the room during filter changes. A caregiver or household member without immunosuppression should perform all filter maintenance.
• Place the used filter immediately into a sealed plastic bag before disposal to prevent re-aerosolization during transport to the trash.
• Wash hands thoroughly after filter handling, even when gloves were used.
• After installing a new filter, run the unit at high speed for 15–30 minutes before the patient re-enters the room to clear any particulate matter disturbed during the change process.

Volatile Organic Compound Sensitivity and Activated Carbon

Some chemotherapy agents cause mucositis — inflammation and ulceration of the mucous membranes — which is associated with heightened sensitivity to chemical irritants including cleaning product VOCs, off-gassing from furniture and flooring, and fragrances. An activated carbon filter stage in the air purifier provides adsorption of these organic compounds and reduces the chemical burden on an already-irritated respiratory tract. For immunocompromised patients, fragrance-free cleaning and personal care products are strongly recommended regardless of air purification measures.

The air purifier carbon filter should also be changed on schedule. Unlike HEPA, a saturated carbon bed does not pose a pathogen re-release risk, but it loses adsorption capacity and provides no VOC benefit when fully loaded.

Air Purifiers Are a Supplemental Measure for Cancer Patients — Not a Substitute for Oncology Infection Control Protocols

The evidence base for home HEPA filtration in immunocompromised patients is based on the known reduction of airborne Aspergillus spore concentration by HEPA filtration, the established causal relationship between airborne conidia concentration and IPA incidence, and the CDC guidance recommending HEPA in the home environment for severely immunocompromised patients. What the evidence does not support is the claim that home HEPA filtration prevents IPA with the certainty achievable in a hospital isolation room.

The reasons for this limitation are structural. A home cannot achieve positive pressure relative to surrounding spaces without clinical HVAC engineering. A home HEPA purifier processes room air in a recirculating loop — it does not filter incoming air from doors, windows, or the HVAC system with the completeness of a hospital supply air system. The home contains sources of Aspergillus that a hospital room does not: houseplants, potting soil, outdoor footwear, and ambient outdoor air infiltration.

The practical hierarchy of protective measures for immunocompromised cancer patients at home:

1. Follow oncologist and infection control team guidance regarding activity restrictions, visitor limitations, and environmental precautions specific to the patient neutrophil nadir and transplant protocol.
2. Avoid environments with high fungal burden: construction sites, gardening, compost, decaying plant matter, caves.
3. Remove houseplants and potting soil from the patient living environment — both are significant Aspergillus sources.
4. Run H13 or H14 HEPA air purifier continuously in the patient bedroom, targeting ≥4 ACH, preferably ≥8 ACH during periods of profound neutropenia.
5. Avoid all ozone-generating devices, ionizers, fragrances, and chemical irritants in the patient environment.
6. Maintain strict filter change protocols with glove use and patient exclusion from the room during changes.

A HEPA air purifier is a meaningful tool in this hierarchy — but it occupies position four, not position one. No air purifier replaces the clinical infection control infrastructure established by the oncology team. Patients and caregivers should not interpret the presence of a HEPA purifier as providing hospital-equivalent protection.